A-PBITMO

A-PBITMO is a synthetic cannabinoid receptor agonist that has been sold as a designer drug, first reported in Germany in July 2023,^[1] and also subsequently identified in Russia.^[2] It has an unusual 1,3-dihydrobenzimidazole-2-thione core structure which has not previously been seen in cannabinoid designer drugs.

References

↑ "New psychoactive substances - the current situation in Europe". European Drug Report. European Union Drugs Agency (EUDA). 2024. https://www.euda.europa.eu/sites/default/files/pdf/31883_en.pdf?606797.
↑ (in Russian) Psychoactive products market observation. Trend analysis. (Report). Aipsin. February 2024. doi:10.13140/RG.2.2.10176.92163.

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/A-PBITMO. Read more

[1] "New psychoactive substances - the current situation in Europe". European Drug Report. European Union Drugs Agency (EUDA). 2024. https://www.euda.europa.eu/sites/default/files/pdf/31883_en.pdf?606797.

[2] (in Russian) Psychoactive products market observation. Trend analysis. (Report). Aipsin. February 2024. doi:10.13140/RG.2.2.10176.92163.

[1]

[2]

A-PBITMO

Topic: Chemistry

See also

References